Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes medication.
The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India ( CDSCO).
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing.
"The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said.
India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further, he added.
"We are now gearing up to launch the product expeditiously through our commercialisation partners in India," Mittal stated.
Biocon shares were trading 0.81 per cent up at Rs 336.75 apiece on BSE.
The company has received approval for its Liraglutide drug substance and its wholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India ( CDSCO).
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing.
"The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said.
India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further, he added.
"We are now gearing up to launch the product expeditiously through our commercialisation partners in India," Mittal stated.
Biocon shares were trading 0.81 per cent up at Rs 336.75 apiece on BSE.
You may also like
These 2 Electric Cars of Mahindra Are Winning Big — 10,000 Units Sold, Tata Motors Feels the Heat
Career Planning: When there are many options in front of you, how to choose the right course? Better skills will get you the job of your choice..
Arsenal heroes drank 35 pints in one sitting as team-mate thought he was 'going to die'
Punch and Baleno Watched on as This ₹6 Lakh SUV Made Its Mark — Over 2 Lakh Sold!
Arthrits: Do you have trouble getting up or sitting due to joint pain? These home remedies will give you quick relief from joint pain..
